Company prepares for the next phase of profitable growth, market expansion, and digital transformation. Industrialization and Energy Services Company (“TAQA”), a global leader in energy and industrial services, today announced that Khalid Nouh will step down from his role as Chief Executive Officer, effective 31 May 2025, as part of the company's ongoing evolution and […]
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your NET Power, Inc. (NYSE:NPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/net-power-inc-lawsuit-submission-form?prid=150632&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150631&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
(NASDAQ:TSHA), DALLAS, May 28, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire May 29, 2025 DALLAS, May 28, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous
(NasdaqGM:IOVA), NEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company's securities between May 9, 2024
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. – IOVA GlobeNewswire May 29, 2025 NEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to
(NYSE:CODI), NEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 8, 2025 to file lead plaintiff applications in a securities class action lawsuit against Compass Diversified Holdings (NYSE: CODI), if they purchased the Company's securities between May 1, 2024 and May 7, 2025,
COMPASS DIVERSIFIED SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Compass Diversified Holdings – CODI GlobeNewswire May 29, 2025 NEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 8, 2025 to
(NYSE:OGN), NEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company's securities between October 31, 2024 and April 30, 2025,